Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Insulin growth factor-like family member 3 (IGFL3) is a small secreted protein consisting of 125 amino acids, encoded by the IGFL3 gene in humans[2][7]. It is a member of the insulin-like growth factor (IGF) superfamily, which includes several growth factor signaling proteins important for cellular energy metabolism and development[4]. IGFL3 is evolutionarily conserved and primarily found in vertebrates, but its precise physiological function remains unclear and is currently subject to investigation. No experimental evidence has been documented for direct involvement in signal transduction, disease processes, or therapeutic targeting in humans to date[6][7]. Although categorized within a superfamily containing critical hormones, IGFL3 itself has no established role as a therapeutic target, nor are there any reported drug interactions, biomarker applications, or notable safety concerns[7]. It is generally referenced as a potential signaling molecule due to sequence homology with IGF family members, but biological data remain sparse. **Summary of key points:** - The most accurate, recognized name is "Insulin growth factor-like family member 3" (IGFL3)[2][7]. - Abundant alternative names and identifiers exist, but none describe a receptor, enzyme, transporter, or major druggable protein class. - As of current knowledge, IGFL3 is *not* a validated or widely investigated drug target, and has minimal disease association. - It should not be confused with IGFBP-3 (Insulin-like growth factor-binding protein 3), a distinct, well-studied IGF pathway protein involved in cancer and metabolism, which is a separate molecule entirely[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin growth factor-like family member 3 (IGFL3).